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Abstract
Purpose The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, 
pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these mark-
ers can differentiate between patient responses for switching adjuvant endocrine therapy after 2–3 years from tamoxifen to 
exemestane and continued tamoxifen monotherapy in the Intergroup Exemestane Study (IES).
Methods Of the 4724 patients in IES, 1506 were managed in a subset of centres (N = 89) participating in PathIES. These 
centres recruited 1282 (85%, 1282/1506) women into PathIES of whom 1036 had phospho-marker data. All phospho-markers 
were analysed by immunohistochemistry staining. Multivariable Cox proportional hazards models of the phospho-markers 
for disease-free survival (DFS) and overall survival (OS) were adjusted for clinicopathological factors. Treatment effects on 
the biomarker expression were determined by interaction tests. Benjamini–Hochberg adjustment for multiple testing with a 
false discovery rate of 10% was applied (pBH).
Results Phospho-T202/T204MAPK, pS118ERα and pS167ERα were all found to be correlated (pBH = 0.0002). These markers 
were not associated with either DFS or OS when controlling for the established clinicopathological factors. Interaction terms 
between the phospho-markers and treatment strategies for either DFS or OS were not statistically significant (pBH > 0.05 
for all).
Conclusions This PathIES study confirmed previously described associations between the phosphorylation site markers 
of AKT, MAPK and ERα activity in postmenopausal breast cancer patients. No prognostic correlations between the phos-
phorylation markers and clinical outcome were found, nor were they predictive for clinical outcomes among patients who 
switched therapy over those treated with tamoxifen alone.
Keywords Breast cancer · Aromatase · Tamoxifen · Prognosis · Biomarkers
Background
Globally, around 1.7 million new breast cancer cases are 
diagnosed each year, with over 550,000 patients who suc-
cumb to the disease [1]. The majority of cases (70–80%) 
are diagnosed with estrogen-receptor alpha (ERα)-positive 
disease and these patients routinely receive endocrine thera-
peutics as adjuvant treatment following surgery. The most 
commonly prescribed endocrine therapies in the adjuvant 
treatment of breast cancer are tamoxifen, or in postmeno-
pausal women aromatase inhibitors (AIs) or sequential treat-
ment of the two. The Intergroup Exemestane Study (IES) 
Zsolt Szijgyarto and Koen D. Flach have contributed equally to 
this work.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1054 9-018-05110 -x) contains 
supplementary material, which is available to authorized users.
 * R. Charles Coombes 
 c.coombes@imperial.ac.uk
Extended author information available on the last page of the article
 Breast Cancer Research and Treatment
1 3
reported superiority of tamoxifen for 2–3 years followed by 
AIs, as compared to tamoxifen alone [2]. These findings 
were confirmed in a recent meta-analysis, which has shown 
that aromatase inhibitors, given at some point during the 
treatment (either at the start or after 2–3 years prior tamox-
ifen exposure) outperforms tamoxifen monotherapy [3].
Currently, it remains elusive whether suitable biomark-
ers can be identified that would facilitate optimal endocrine 
treatment selection in the adjuvant treatment of breast can-
cer, identifying individual patients who would derive selec-
tive benefit from tamoxifen, AIs or sequential treatment. Our 
previous analyses showed that high expression of ERß is 
indicative of no benefit in switching [4]. In contrast, high 
levels of cell proliferation marker Ki67 indicated selective 
benefit of AIs over tamoxifen alone [5].
Phosphorylation of ERα at serine residues 118 and 167 by 
MAPK and AKT, respectively, increases its activity (Online 
Resource 1) and phosphorylation at these sites has been 
associated with patient response to tamoxifen [6, 7]. In con-
trast, Beelen et al. showed an indication of tamoxifen resist-
ance in postmenopausal breast cancer patients with activated 
MAPK [8]. No studies to date assessed potential associations 
of phosphorylation of ERα, MAPK or AKT in patients who 
received both tamoxifen and aromatase inhibitor treatment, 
and how this compares to tamoxifen alone. To this end, these 
phospho-modifications as potential biomarkers for selective 
endocrine therapy benefit were tested, as determined in the 
IES study. Additionally, immunohistochemistry (IHC) for 
active MAPK (phosphorylated at threonine residues 202 and 
204) as well as AKT (phosphorylated at threonine 308 and 
serine 473) was undertaken, since these kinases are known 
to phosphorylate ERα. Specifically, MAPK phosphorylates 
S118ERα [9, 10], while AKT stimulates the phosphoryla-
tion of S167ERα [11]. Although reports using phospho-spe-
cific antibodies have indicated that these post-translational 
modifications can have an impact on patient’s outcome after 
adjuvant endocrine treatment [6, 7], none of these factors 
has been tested for biomarker potential in the context of a 
randomised clinical trial, directly comparing outcome after 
sequential tamoxifen/AI or tamoxifen alone.
Our hypothesis was that activated MAPK and/or AKT 
pathways—and their downstream impact on ERα phospho-
rylation at S118 and S167—might be predictive of differ-
ential treatment benefit of patients who were treated with 
tamoxifen alone or who received tamoxifen/exemestane 
switched therapy.
Our aims in this study were therefore three-fold: firstly, to 
assess the prognostic significance of the ERα phosphoryla-
tion markers in the entire study cohort regardless of treat-
ment received. Secondly, to determine the correlations of 
the ERα phosphorylation with the respective kinases. Lastly, 
we aimed to determine whether these markers would indi-
cate selective treatment benefit for patients receiving either 
tamoxifen alone or for those patients who switched to an AI 
after 2–3 years of tamoxifen.
Methods
Patients, data handling and sample collection
The study design, detailed eligibility criteria and treatment 
schedules have been previously described [2]. IES was a 
multicentre, international, randomised, double-blind phase 
III study, comparing exemestane 25 mg/day to tamoxifen 
20 mg/day (30 mg in Denmark) prescribed for 2–3 years 
in postmenopausal women with ER+/unknown primary 
breast cancer who remained disease free after receiving 
adjuvant tamoxifen therapy for 2 to 3 years [4]. The IES 
study recruited in total 4724 postmenopausal women from 
37 countries (366 centres) between 1998 and 2003 [4]. For-
malin-fixed paraffin-embedded (FFPE) tumour samples were 
retrospectively collected from a subset of centres (PathIES 
centres N = 89) in accordance with institutional guidelines, 
ethics requirements and national laws. Of 1506 IES patients 
managed by PathIES centres, pathological samples from 
the primary surgery (at least 2 years before randomisation) 
were collected retrospectively from 1282 women recruited 
in PathIES centres (85.1%) [4].
All clinical data used in the analyses were based on the 
snapshot taken for the most recent IES clinical publica-
tion (median follow-up time was 91 months) [12] and the 
REMARK criteria were employed for data reporting [13].
Immunohistochemistry staining
Tissue microarrays (TMAs) were constructed using for-
malin-fixed paraffin-embedded (FFPE) tumour blocks with 
a total of two cores per tumour. For details on antibodies, 
staining and scoring, see Online Resource methods section.
Statistical analyses
Spearman’s correlation coefficients (rS) were obtained to 
investigate the associations between the continuous vari-
ables of phospho-markers (pT202/T204MAPK, pS118ERα 
and pS167ERα) and ERα, PR and Ki67. Trend test was used 
to assess association for ordinal variables (HER2 status, 
pT308AKT, pT473AKT and other dichotomised phospho-
markers). Chi-squared (χ2) test was applied to investigate the 
association between the baseline characteristics of partici-
pants who did and did not provide tumour samples within 
PathIES participating centres. Disease-free survival (DFS) 
was defined as time from randomisation to recurrence (local, 
distant ipsilateral or contralateral) or death without disease 
relapse (intercurrent death) or censoring to the last date the 
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patient was known to be alive and event free. Overall sur-
vival (OS) was defined as time from randomisation to date 
of death or censoring to the last date the patient was known 
to be alive.
The distributions of DFS and OS according to the sub-
groups of the phospho-markers were estimated using 
Kaplan–Meier plots censored at 10 years. Univariate and 
multivariable Cox proportional hazard (PH) survival models 
were applied to estimate hazard ratios (HR) for DFS and OS. 
All univariate and multivariable models met the PH assump-
tion investigated with Schoenfeld residuals and PH tests.
For each of the phospho-markers (pT308AKT, 
pT473AKT, pT202/T204MAPK, pS118ERα and 
pS167ERα), a CoxPH regression model was fitted in the 
whole study, regardless of treatment received to assess the 
prognostic effect on DFS and OS via estimation of hazard 
ratios and 95% confidence intervals (CI). CoxPH models 
were fitted with and without adjusting for pre-specified prog-
nostic factors of the centrally assessed estrogen-receptor sta-
tus (H score), progesterone-receptor status (H score), Ki67 
(ln(ki67 + 0.1)), HER2 status, treatment (tamoxifen and 
exemestane), nodal status, age group, tumour grade and size 
(ln(size)). Missing values of the clinicopathological vari-
ables were assumed as missing at completely random and 
therefore not imputed. In the multivariable survival model-
ling, interaction tests were used to investigate whether there 
is a differential treatment effect within phospho-marker-
defined subgroups.
P-values for all statistical tests were two sided and Ben-
jamini–Hochberg adjusted for multiple testing with false 
discovery rate of 10%. If the Benjamini–Hochberg adjusted 
P-value (pBH) was less than 0.05, the test was considered 
statistically significant.
Results
PathIES participants
Of the 4724 postmenopausal women with ERα-positive/
unknown primary breast cancer in IES trial, 1506 were man-
aged in 89 centres participating in PathIES study (Fig. 1; 
Table 1). These centres recruited 1282 (85%, 1282/1506) 
women into PathIES of whom 1036 had phospho-marker 
data (Fig. 1; Table 1 and Online Resource 4).
Staining and scoring of the phospho‑markers
Representative images of immunostaining for each marker 
with range of intensity are shown in Fig. 2. Good agree-
ment was found between the independent observers when 
assessing the expression levels of the phospho-markers 
(Online Resource 5). Phospho-T308AKT, pS473AKT, 
pT202/T204MAPK and pS167ERα were detectable in 
47.4% (297/627), 51.1% (348/681), 46.8% (316/675) and 
52.7% (329/624) of the tumour samples, respectively 
(Table 2, Online Resource 6, 7). 51.3% (400/780) of the 
patients had pS118ERα of 0–40% and 48.7% (380/780) 
presented pS118ERα of ≥ 50% (Table 2, Online Resource 
6, 7). Previous studies regarding pT202/T204MAPK, 
pS118ERα and/or pS167ERα often made use of a nega-
tive versus positive cut-off comparison [14–17], a cut-
off point we also used for our pT202/T204MAPK and 
pS167ERα stainings. For the pS118ERα, however, we 
used a median based cut-off, yielding well-balanced 
groups by treatments (Table  2). Additionally, this 
approach allowed us to prevent the risk of any spuriously 
significant result associated with the use of optimal cut-
off points [18, 19].
pS167ERα score
(N = 548) 
pS473AKT intensity 
data (N = 681) 
pT202/T204MAPK
score (N = 678) 
pT308AKT intensity 
data (N = 627) 
pS118ERα score
(N = 780)
IES patients in centres participating 
in PathIES (N = 1506)
Patients recruited to PathIES
(N = 1282)
Participants in PathIES with any 
biomarker data (N = 1036)
Fig. 1  PathIES participants. Flow chart for PathIES participants with 
phospho-marker data
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Table 1  Baseline characteristics 
of PathIES participants PathIES Centres provided tissues (N = 1506) Centres not provided 
tissues
Participants 
with any BM 
scores
χ2 test 
within cen-
tre, p
Participants 
without tis-
sues/any BM 
scores
χ2 test with and with-
out tissue provided, p
Participants 
without tis-
sue/any BM 
scores
Total 
N = 1036
Total 
N = 470
Total 
N = 3218
N % N % N %
Treatment
 A—exemestane 534 51.5 224 47.7 1594 49.5
 B—tamoxifen 502 48.5 246 52.3 1624 50.5
0.16
0.20
Age (years)
 < 60 347 33.5 145 30.9 1031 32.0
 60–69 452 43.6 220 46.8 1349 41.9
 70 + 237 22.9 105 22.3 838 26.0
0.48
0.20
Grade (G)
 G1 186 18.0 86 18.3 517 16.1
 G2 453 43.7 180 38.3 1354 42.1
 G3/undifferentiated 199 19.2 79 16.8 645 20.0
 Not assessable 10 1.0 17 3.6 76 2.4
 Unknown 188 18.1 108 23.0 626 19.5
0.60a
0.60
Nodes (N)
 N− 447 43.1 229 48.7 1171 55.0
 1–3 N + 371 35.8 149 31.7 911 28.3
 > 3 N + 159 15.3 55 11.7 444 13.8
 Unavailable 59 5.7 37 7.9 92 2.9
0.03
< 0.001
Tumour size (cm)
 ≤ 2 596 57.5 290 61.7 1899 59.0
 > 2 and ≤ 5 393 37.9 152 32.3 1171 36.4
 > 5 31 3.0 7 1.5 84 2.6
 Unavailable 16 1.6 21 4.5 64 2.0
0.04
0.33
Histology type
 Infiltrating ductal 768 74.1 336 71.5 2503 77.8
 Infiltrating lobular 160 15.5 65 13.8 437 13.6
 Other 108 10.4 69 14.7 269 8.4
 Unavailable 0 0 0 0 9 0.2
0.05
0.13
Previous CT use
 No 839 81.0 364 77.4 1979 61.5
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Correlations between phospho‑markers and clinical 
variables
As MAPK and AKT signalling cascades are functionally 
implicated in phosphorylation events on ERα, we next tested 
correlations between all phospho-markers of interest. All 
phospho-markers of MAPK and ERα (pT202/T204MAPK, 
pS167ERα and pS118ERα) are positively correlated, albeit 
moderately [Spearman’s correlation coefficients rS (pT202/
T204MAPK/pS118ERα) = 0.62, rS (pT202/T204MAPK/
pS167ERα) = 0.58, rS (pS167ERα/pS118ERα) = 0.59], 
yet highly statistically significant (pBH = 0.0002 for all) 
(Table 3).
Furthermore, phosphorylation status of both pT308AKT 
and pS473AKT was associated with high levels of pT202/
T204MAPK, pS167ERα and pS118ERα (pBH < 0.001 for all) 
(Table 4). Similarly, a positive trend was found when com-
paring pT308AKT and pS473AKT (Table 4). These find-
ings support the known biological connections between ERα 
phosphorylation status and activity of MAPK and AKT.
The Spearman’s correlation of pT202/T204MAPK, 
pS167ERα and pS118ERα with PR status and Ki67 was 
overall negligible (Table 3). Exploring the distribution 
of dichotomised phospho-markers by HER2 status, we 
found more patients with pT308AKT (71%, pBH = 0.03) or 
pS473AKT intensity (69%, pBH = 0.06) in the HER2-positive 
group (Table 5).
The distribution of the dichotomised phospho-markers 
among the groups of clinical and pathological character-
istics is summarised in Online Resource 8, demonstrat-
ing that patients with high pT202/T204MAPK (≥ 10%), 
or pS118ERα (≥ 50%) present with lower grade tumours 
 [pBH (pT202/T204MAPK) = 0.01, pBH (pS118ERα) = 0.05) 
and smaller tumour size (pBH (pT202/T204MAPK) = 0.01, 
pBH (pS118ERα) = 0.01). Similarly, patients with high 
pS167ERα (≥ 10%) seemed to have smaller tumours (pBH 
(pS167ERα) = 0.03]. Finally, a negative trend was observed 
between age and pT202/T204MAPK as well as pS118ERα; 
however, these trends were not statistically significant at 
10% false discovery rate: older patients tend to have lower 
phosphorylation levels of MAPK (pBH = 0.07) and ERα-
S118 (pBH = 0.07) (Online Resource 8).
Associations of phospho‑markers with DFS and OS 
outcomes
The potential associations of pS118ERα, pS167ERα, 
pT202/T204MAPK, pT308AKT and pS473AKT with out-
come, and their relation to therapy were explored. Firstly, 
Kaplan–Meier estimates for DFS as primary endpoint for 
IES were analysed for all patients irrespective of therapy. 
No statistically significant difference in DFS estimates was 
observed for any of the factors tested (log-rank pBH > 0.05) 
(Figs. 3, 4, Online Resource 9, 10, 11). When investigating 
Comparison of patient’s baseline characteristics who did and did not provide tumour samples within 
PathIES participating centres
BM biomarker, CT chemotherapy, HRT hormonal replacement therapy
a χ2 test includes G1, G2 and G3/undifferentiated groups only
Table 1  (continued) PathIES Centres provided tissues (N = 1506) Centres not 
provided 
tissues
Participants 
with any BM 
scores
χ2 test 
within cen-
tre, p
Participants 
without tis-
sues/any BM 
scores
χ2 test with and with-
out tissue provided, p
Participants 
without tis-
sue/any BM 
scores
Total 
N = 1036
Total 
N = 470
Total 
N = 3218
N % N % N %
 Yes 197 19.0 106 22.6 1239 38.5
0.11
< 0.001
HRT use
 No 677 65.3 111 23.6 690 21.4
 Yes 323 31.2 333 70.9 2477 77.0
 Unknown 36 3.5 26 5.5 51 1.6
0.005
< 0.001
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how patients with different levels of phospho-markers would 
respond to tamoxifen and to switched therapy, no statistically 
significant change in the Kaplan–Meier curves for DFS was 
revealed for any biomarkers.
The effects of the phosphorylation levels of the 
markers on overall survival were also explored with 
Kaplan–Meier curves (Figs. 3, 4, Online Resource 9, 10, 11). 
Phosphorylation levels of the biomarkers were not statisti-
cally significantly associated with the overall survival out-
come of the PathIES participants. Patients with higher levels 
of pT202/T204MAPK (≥ 10%) or pS167ERα (≥ 10%) tend 
to have better OS than those with pT202/T204MAPK of 0% 
(log-rank pBH = 0.05) (Fig. 3e) or pS167ERα of 0% (log-rank 
pBH = 0.05) (Fig. 4e); however, none of these associations 
Fig. 2  Immunostaining panel, depicting representative TMA cores. Representative images of immunostaining for each phospho-marker (pT202/
T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) with range of intensity
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were statistically significant at 10% false discovery rate. The 
association of the levels of the phospho-markers with DFS 
was next tested in the whole PathIES study sample with 
CoxPH survival models. None of the phospho-markers was 
found to be prognostic for DFS either in the univariate or in 
the multivariable CoxPH models adjusting the effect of each 
phospho-marker for the prognostic parameters of ERα, PR, 
HER2, Ki67, tumour size and grade, nodal status, age and 
treatment regimens (Table 6).
When investigating the predictive value of the phospho-
markers with high versus low expression levels on DFS for 
exemestane over tamoxifen in the entire study sample, none 
of the biomarkers’ expression was statistically significant to 
predict differential DFS benefit for patients who switched 
therapy over tamoxifen: the phospho-marker and treatment 
interaction tests were not statistically significant in the mul-
tivariable analyses (pBH corresponding to the interaction 
test > 0.05 for all) (Table 6).
Exploring the effect of pT202/T204MAPK on OS in the 
entire cohort, the crude effect size of pT202/T204MAPK 
of ≥ 10% versus 0% was 0.66 (95% CI 0.47 to 0.94) 
(Table 7). This would suggest an overall survival benefit 
among patients with pT202/T204MAPK of ≥ 10%; how-
ever, this was not statistically significant after adjusting for 
multiple testing at 10% false discovery rate (pBH = 0.06). 
The multivariable analyses further demonstrated that this 
slight association of pT202/T204MAPK with the OS was 
due to the confounding effect of conventional parameters 
(HR 0.67, 95% CI 0.33 to 1.34, pBH = 0.29). Similarly, 
patients (regardless of treatment received) who expressed 
high level of pS167ERα seemed to have a better prognosis 
Table 2  Staining results of 
phospho-markers
Distribution of the phospho-markers by treatment strategies and the associated trend tests
pBH Benjamini–Hochberg adjusted p
Phospho-markers Total Tamoxifen Exemestane Test for trend
N N (%) N (%) pBH
pT308AKT (N = 627)
 No intensity 330 155 (51.7) 175 (53.5) 0.78
 With intensity 297 145 (48.3) 152 (46.5)
pS473AKT (N = 681)
 No intensity 333 160 (48.3) 173 (52.4) 0.78
 With intensity 348 171 (51.7) 177 (47.6)
pT202/T204MAPK (%) (N = 675)
 0 359 160 (49.8) 199 (56.2) 0.40
 ≥ 10 316 161 (50.2) 155 (43.8)
pS118ERα (%) (N = 780)
 0–40 400 185 (49.2) 215 (53.2) 0.43
 ≥ 50 380 191 (50.8) 189 (46.8)
pS167ERα (%) (N = 624)
 0 295 133 (44.6) 162 (49.7) 0.43
 ≥ 10 329 165 (55.4) 164 (50.3)
Table 3  Positive correlation of pT202/T204MAPK, pS167ERα and 
pS118ERα
Spearman’s correlation of the phospho-markers and prognostic fac-
tors
cont. continuous
a n—sample size
b rS—Spearman’s correlation coefficient
c pBH—Benjamini–Hochberg adjusted p
pT202/T204
MAPK (%)
pS118ERα (%) pS167ERα (%)
pS118ERα (%)
 na 608 – –
 rSb 0.62 – –
 pBHc 0.0002
pS167ERα (%)
 n 571 582 –
 rS 0.58 0.59 –
 pBH 0.0002 0.0002
ER (H score)
 n 596 678 540
 rS 0.17 0.25 0.33
 pBH 0.0002 0.0002 0.0002
PR (H score)
 n 563 670 528
 rS 0.12 0.17 0.12
 pBH 0.005 0.0002 0.005
Ki67 (cont.)
 n 499 583 461
 rS 0.01 0.01 0.10
 pBH 0.79 0.79 0.05
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for OS than those with low expression of pS167ERα but 
this association was not statistically significant (crude 
HR 0.66, 95% CI 0.46 to 0.94, pBH = 0.06; adjusted HR 
0.58, 95% CI 0.27 to 1.26, pBH = 0.29) (Table 7). The other 
markers (pS118ERα, pT308AKT and pT473AKT) were 
not prognostic for OS in either univariate or multivariable 
analyses (Table 7).
Interaction tests showed no differential treatment 
(exemestane over tamoxifen) effect on OS within any of 
the phospho-markers-defined subgroups (pBH > 0.05 for all) 
(Table 7).
In post hoc exploratory analyses of the combinations 
of factors within the same biological pathway (pT202/
T204MAPK/pS118ERα, pS473AKT/pS167ERα and 
pT308AKT/pS167ERα), there were no differences observed 
in DFS (Online Resource 12, 13) or OS (Online Resource 
12, 14) outcomes for any of the tested combinations.
Interaction tests between the phospho-markers and treat-
ments demonstrated no predictive value of any pathways 
investigated either on DFS or on OS among patients treated 
with exemestane over tamoxifen when adjusting for potential 
confounders in the entire study sample (all pBH values cor-
responding to the interaction test > 0.05).
Table 4  Positive correlation of 
AKT activation with increased 
phosphorylation levels of 
MAPK and ERα
Distribution of pT202/T204MAPK, pS118ERα and pS167ERα by the groups of phosphorylated AKT and 
the associated trend tests
int. intensity, pBH Benjamini–Hochberg adjusted p
pT308AKT pS473AKT
Total No int. Int. Test for trend Total No int. Int. Test for trend
N N (%) N (%) pBH N N (%) N (%) pBH
pT202/T204 MAPK (%)
 0 292 203 (69) 89 (33) < 0.001 321 195 (68) 126 (41) < 0.001
 ≥ 10 271 90 (31) 181 (67) 273 93 (32) 180 (59)
pS118ERα (%)
 0–40 292 206 (67) 86 (31) < 0.001 320 195 (64) 125 (39) < 0.001
 ≥ 50 290 102 (33) 188 (69) 306 112 (36) 194 (61)
pS167ERα (%)
 0 253 169 (61) 84 (32) < 0.001 262 148 (56) 114 (38) < 0.001
 ≥ 10 287 110 (39) 177 (68) 299 114 (44) 185 (62)
pS473AKT
 No intensity 269 187 (62) 82 (31) < 0.001 – – – –
 Intensity 298 115 (38) 183 (69) – – –
Table 5  Association of phospho-markers with HER2 status
Distribution of the dichotomised phospho-markers by HER2 and the 
associated trend tests
pBH Benjamini–Hochberg adjusted p
HER2 Test for trend
Total Negative Positive
N N (%) N (%) pBH
pT308AKT
 No intensity 224 214 (55) 10 (29) 0.03
 Intensity 202 178 (45) 24 (71)
pS473AKT
 No intensity 215 203 (50) 12 (31) 0.06
 Intensity 230 203 (50) 27 (69)
pT202/T204MAPK (%)
 0 257 230 (55) 27 (64) 0.30
 ≥ 10 205 190 (45) 15 (36)
pS118ERα (%)
 0–40 290 260 (53) 30 (68) 0.09
 ≥ 50 244 230 (47) 14 (32)
pS167ERα (%)
 0 217 195 (50) 22 (54) 0.62
 ≥ 10 217 198 (50) 19 (46)
Fig. 3  Kaplan–Meier DFS and OS estimates for pT202/T204MAPK. 
a DFS and e OS estimates by pT202/T204MAPK groups regard-
less of treatments received. b DFS and f OS estimates by treatments 
for patients with pT202/T204MAPK of 0%. c DFS and g OS esti-
mates by treatments for patients with pT202/T204MAPK intensity 
of ≥ 10%. Forest plots represent the treatment effects of exemestane 
versus tamoxifen on d DFS and h OS in the subgroups of pT202/
T204MAPK as well as in the whole study sample (overall). Hazard 
ratios were estimated with univariate CoxPH models. Test for interac-
tion between exemestane versus tamoxifen and pT202/T204MAPK of 
≥ 10% versus 0% is shown in the forest plots. (p unadjusted, pBH Ben-
jamini–Hochberg adjusted, Tam tamoxifen, Exem exmestane)
▸
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 Overall Survival
 Hazard Ratio (95 % CI) Study Sample
0.83 (0.54 - 1.27)
0.96 (0.56 - 1.65)
0.91 (0.65 - 1.26)
Interaction pBH (p):
0.75 (0.66)
pT202/T204MAPK
(0 %)
pT202/T204MAPK
( 10 %)
Overall
 Exemestane better  Tamoxifen better
0.25 0.50 0.75 1.00 1.25 1.50 1.75
Hazard Ratio
 Disease Free Survival
 Hazard Ratio (95 % CI) Study Sample
0.77 (0.53 - 1.12)
0.92 (0.60 - 1.41)
0.84 (0.64 - 1.12)
Interaction pBH (p):
0.81 (0.56)
pT202/T204MAPK
(0 %)
pT202/T204MAPK
(≥10 %)
Overall
 Exemestane better  Tamoxifen better
0.25 0.50 0.75 1.00 1.25 1.50 1.75
Hazard Ratio
Log-rank pBH (p) = 0.57 (0.15)
0
25
50
75
100
314 292(17) 267(21) 236(19) 119(15) 10(11)≥10 % :
359 329(25) 287(37) 248(24) 113(17) 7(6)0 % :
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
pT202/T204MAPK (0 %)
pT202/T204MAPK ( 10 %)
pT202/T204MAPK (0 %)
Log-rank pBH (p) = 0.30 (0.18)
0
25
50
75
100
199 186(11) 163(19) 142(12) 68(8) 4(5)Exem.
160 143(14) 124(18) 106(12) 45(9) 3(1)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
pT202/T204MAPK ( 10 %)
Log-rank pBH (p) = 0.93 (0.70)
0
25
50
75
100
153 143(8) 132(8) 116(9) 60(7) 4(7)Exem.
161 149(9) 135(13) 120(10) 59(8) 6(4)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
Log-rank pBH (p) = 0.05 (0.02)
0
25
50
75
100
314 303(6) 280(18) 254(11) 133(12) 10(6)10 % :
359 338(16) 307(26) 273(18) 125(16) 7(8)0 % :
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
pT202/T204MAPK (0 %)
pT202/T204MAPK ( 10 %)
pT202/T204MAPK (0 %)
Log-rank pBH (p) = 0.39 (0.39)
0
25
50
75
100
199 187(10) 174(9) 151(13) 74(6) 4(5)Exem.
160 151(6) 133(17) 122(5) 51(10) 3(3)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
pT202/T204MAPK ( 10 %)
Log-rank pBH (p) = 0.92 (0.89)
0
25
50
75
100
153 149(2) 136(9) 124(3) 64(6) 4(5)Exem.
161 154(4) 144(9) 130(8) 69(6) 6(1)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
g h
a b
c d
e f
≥
≥
≥
≥
≥
≥
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 Overall Survival
 Hazard Ratio (95 % CI) Study Sample
0.66 (0.41 - 1.06)
0.93 (0.53 - 1.61)
0.79 (0.55 - 1.14)
Interaction pBH (p):
0.75 (0.34)
pS167ER
(0 %)
pS167ER
( 10 %)
Overall
 Exemestane better  Tamoxifen better
0.25 0.50 0.75 1.00 1.25 1.50 1.75
Hazard Ratio
 Disease Free Survival
 Hazard Ratio (95 % CI) Study Sample
0.70 (0.45 - 1.08)
0.79 (0.51 - 1.22)
0.75 (0.55 - 1.01)
Interaction pBH (p):
0.81 (0.68)
pS167ER
(0 %)
pS167ER
( 10 %)
Overall
 Exemestane better  Tamoxifen better
0.25 0.50 0.75 1.00 1.25 1.50 1.75
Hazard Ratio
Log-rank pBH (p) = 0.57 (0.57)
0
25
50
75
100
329 309(14) 280(23) 242(21) 114(17) 10(9)10 % :
295 271(20) 242(25) 214(18) 103(10) 5(8)0 % :
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
pS167ERα (0 %)
pS167ER  (≥10 %)
pS167ER  (0 %)
Log-rank pBH (p) = 0.30 (0.10)
0
25
50
75
100
162 155(5) 138(13) 120(12) 62(3) 4(6)Exem.
133 116(15) 104(12) 94(6) 41(7) 1(2)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
pS167ER  ( 10 %)
Log-rank pBH (p) = 0.93 (0.29)
0
25
50
75
100
164 153(8) 140(10) 123(8) 63(6) 1(5)Exem.
165 156(6) 140(13) 119(13) 51(11) 9(4)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
Log-rank pBH (p) = 0.05 (0.02)
0
25
50
75
100
329 316(7) 296(13) 261(14) 131(10) 10(7)≥10 % :
295 280(11) 256(20) 235(11) 109(16) 5(9)0 % :
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
pS167ER  (0 %)
pS167ER  ( 10 %)
pS167ER  (0 %)
Log-rank pBH (p) = 0.39 (0.08)
0
25
50
75
100
162 158(2) 146(8) 131(9) 64(7) 4(5)Exem.
133 122(9) 110(12) 104(2) 45(9) 1(4)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
pS167ER  ( 10 %)
Log-rank pBH (p) = 0.92 (0.79)
0
25
50
75
100
164 156(5) 146(6) 130(4) 69(3) 1(6)Exem.
165 160(2) 150(7) 131(10) 62(7) 9(1)Tam.
Number at risk (events)
0 2 4 6 8 10
Time from randomisation (years)
Tam.
Exem.
a b
c d
e f
g h
α
≥α
α
α ≥
≥α
≥
α
α
≥
≥
α
α
α
α
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Discussion
In the adjuvant treatment of breast cancer, multiple endo-
crine therapeutic options are available and current guide-
lines permit the use of tamoxifen, aromatase inhibitors or a 
sequential treatment of the two. Therefore, biomarkers are 
needed to enable optimal endocrine treatment selection. In 
this study, we used samples from the Intergroup Exemes-
tane Study to evaluate whether there is predictive value of 
biomarkers in the MAPK/AKT/ERα signalling axis selec-
tive for patients receiving either tamoxifen monotherapy or 
tamoxifen/exemestane sequential treatment. While multiple 
studies have described an association between tamoxifen 
response and phosphorylation status of these factors [6–8], 
such connections are thus far not reported in patients who 
received both tamoxifen and aromatase inhibitor treatment.
Several studies [14, 20–22], including our own [23–25], 
have evaluated co-expression of relevant MAPK and AKT 
pathways with kinases with ERα phosphorylation status; in 
general, these studies have reported a correlation between 
pS118ERα, pS167ERα and the activation status of respec-
tive kinases, i.e. MAPK and AKT. Our current study con-
firms these findings, further supporting the quality of our 
dataset.
In the context of PathIES study, the phospho-markers of 
our interest did not appear to be prognostic for DFS in the 
entire cohort regardless of treatment received or predictive 
for this outcome among patients with switched therapy (to 
exemestane from tamoxifen), over those treated with tamox-
ifen alone when adjusting for potential confounders.
Phospho-S167ERα has previously been shown to be 
positively correlated with PR [26] and, by our group, nega-
tively with tumour size [24]. Although it has been reported 
that pS167ERα is indicative of good outcome in patients 
who received adjuvant tamoxifen [24, 26, 27], the present 
study demonstrated that this biomarker is neither prognostic 
for DFS or OS nor predictive for these outcomes among 
PathIES patients managed with exemestane after tamoxifen 
when controlling for conventional prognostic factors.
In terms of effect on prognosis, several studies have 
been published examining the effect of pS118ERα where 
this marker correlates with PR [28] and is negatively corre-
lated with grade [25]. As the association of pS118ERα with 
outcome is most profound in pre-menopausal patients [16], 
any potential inconsistency of our findings with previous 
reports may be related to differences in menopausal status. 
Furthermore, our group has previously shown an association 
Fig. 4  Kaplan–Meier DFS and OS estimates for pS167ERα. a DFS 
and e OS estimates by pS167ERα groups regardless of treatments 
received. b DFS and f OS estimates by treatments for patients with 
pS167ERα of 0%. c DFS and g OS estimates by treatments for 
patients with pS167ERα intensity of ≥ 10%. Forest plots represent 
the treatment effects of exemestane versus tamoxifen on d DFS and 
h OS in the subgroups of pT202/T204MAPK as well as in the whole 
study sample (overall). Hazard ratios were estimated with univari-
ate CoxPH models. Test for interaction between exemestane versus 
tamoxifen and pS167ERα of ≥ 10% versus 0% is shown in the forest 
plots. (p unadjusted, pBH Benjamini–Hochberg adjusted, Tam tamox-
ifen, Exem exmestane)
◂
Table 6  Association of the 
phospho-markers with disease-
free survival (DFS)
Univariate and multivariable CoxPH analyses of phospho-markers with DFS
CI confidence intervals, pBH Benjamini–Hochberg adjusted p
a Adjusted for ER, PR, HER2, Ki67, tumour size and grade, nodal status, age and treatment
b Interaction between biomarker and exemestane versus tamoxifen
Phospho-markers Univariate CoxPH Multivariable  CoxPHa
HR (95% CI) pBH HR (95% CI) pBH Int.b  pBH
pT308AKT
 No intensity 1.00 1.00
 With intensity 0.89 (0.66–1.21) 0.57 1.26 (0.68–2.35) 0.90 0.90
pS473AKT
 No intensity 1.00 1.00
 With intensity 1.09 (0.89–1.45) 0.57 0.94 (0.53–1.66) 0.90 0.90
pT202/T204MAPK (%)
 0 1.00 1.00
 ≥ 10 0.81 (0.61–1.08) 0.57 0.88 (0.49–1.56) 0.90 0.90
pS118ERα (%)
 0–40 1.00 1.00
 ≥ 50 0.86 (0.65–1.12) 0.57 0.65 (0.40–1.06) 0.72 0.90
pS167ERα (%)
 0 1.00 1.00
 ≥ 10 0.92 (0.67–1.24) 0.57 0.96 (0.53–1.76) 0.90 0.90
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between pT202/T204MAPK and smaller tumour size, and 
better survival outcome in ERα-positive breast cancer 
patients [24]. The present study appears to confirm the nega-
tive associations of both factors (pT202/T204MAPK and 
pS118ERα) with prognostic features such as tumour size, 
yet no significant association with outcomes was observed 
in this cohort for either phosphorylation marker.
Activation of the phosphatidyl-inositol-3 kinase pathway 
as measured by phosphorylation status of components of the 
protein cascade has been shown to correlate with tamox-
ifen resistance, while this was not found for its upstream 
drivers like the presence of a PIK3CA hotspot mutation, 
or PTEN loss [29, 30]. AKT inhibitors have been shown to 
extend the duration of response to both tamoxifen and AI in 
pre-clinical models [31]. It has also been reported that high 
AKT activity, as defined by phosphorylation at serine 473 
and threonine 308, does not predict for significant benefit 
from tamoxifen [8]. In this study, the correlations between 
AKT phosphorylation and poor prognosis in ERα-positive 
patients were not observed, although high expression of its 
downstream target p-p70S6K had been reported to confer a 
favourable prognosis in postmenopausal patients [8]. Data 
in this study which supported the correlations with conven-
tional prognostic factors, AKT phosphorylation, however, 
showed no independent impact on prognosis in this ran-
domised phase III study population.
Conclusion
This study of 1036 primary tumours confirms the association 
between activated AKT, MAPK and ERα phosphorylation 
status in postmenopausal breast cancer patient, but does not 
corroborate their prognostic power for DFS or OS in the 
entire PathIES study, nor their predictive values for these 
outcomes for patients managed by switched therapy over 
tamoxifen alone.
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